About anbio biotechnology - NNNN
Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is headquartered in Frankfurt, Germany.
NNNN At a Glance
Anbio Biotechnology
Wilhelm Gutbrod Street, 21B
Frankfurt, Hessen 60437
| Phone | 49-16-96247281 | Revenue | 9.76M | |
| Industry | Medical Specialties | Net Income | 7.23M | |
| Sector | Health Technology | 2025 Sales Growth | 10.22% | |
| Fiscal Year-end | 12 / 2026 | Employees | 27 | |
| View SEC Filings |
NNNN Valuation
| P/E Current | 163.67 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 182.685 |
| Price to Sales Ratio | 135.245 |
| Price to Book Ratio | 37.267 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 200.609 |
| Enterprise Value to Sales | 133.813 |
| Total Debt to Enterprise Value | N/A |
NNNN Efficiency
| Revenue/Employee | 361,431.018 |
| Income Per Employee | 267,659.524 |
| Receivables Turnover | 2.272 |
| Total Asset Turnover | 0.354 |
NNNN Liquidity
| Current Ratio | 344.311 |
| Quick Ratio | 344.311 |
| Cash Ratio | 135.494 |
NNNN Profitability
| Gross Margin | 87.236 |
| Operating Margin | 66.703 |
| Pretax Margin | 74.055 |
| Net Margin | 74.055 |
| Return on Assets | 26.226 |
| Return on Equity | 27.16 |
| Return on Total Capital | 20.406 |
| Return on Invested Capital | 27.16 |
NNNN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |